Understanding ESR1 Mutations in Metastatic Breast Cancer Testing and Implications Guide

The emergence of novel treatments has cemented ESR1 mutation testing in key breast cancer clinical practice guidelines. While these guidelines currently recommend ESR1 mutation testing at clinical progression following first-line (1L) hormone therapy, emerging clinical data is paving the way for ESR1 mutation surveillance during 1L therapy to intervene with effective therapies before a patient experiences anatomical progression. 

Find out more on relevant clinical data and about the importance of ESR1 mutation testing through our insightful educational guide!